Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Moving Toward PAT Standardized Nomenclature And Definitions

This article was originally published in The Pink Sheet Daily

Executive Summary

The process analytical technology component of FDA's drug quality initiative will be assisted by an independent standards-making effort and agency encouragement of comparability protocols. Part 11 and dispute resolution are other quality initiative components drawing industry input.
Advertisement

Related Content

FDA Expects 25 Formal Dispute Resolution Requests Annually On GMP Issues
FDA Expects 25 Formal Dispute Resolution Requests Annually On GMP Issues
Rapid Microbiology Methods Submissions Reviewed By Special FDA Team
Rapid Microbiology Methods Submissions Reviewed By Special FDA Team
FDA's "Critical Path" Leads To Pharmaceutical Science Advisory Committee Meeting
FDA's "Critical Path" Leads To Pharmaceutical Science Advisory Committee Meeting

Topics

Advertisement
UsernamePublicRestriction

Register

PS060172

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel